Gilead Hepsera Launch: Lamivudine-Resistant Hep B Is First Target
Gilead's roll-out of Hepsera should be helped by a readily identifiable population of approximately 12,000 hepatitis B patients who are resistant to lamivudine (GlaxoSmithKline's Epivir-HBV)
You may also be interested in...
Gilead is launching the hepatitis B agent Hepsera (adefovir) at a wholesale acquisition cost of $440 per month
Gilead's adefovir dipivoxil patients should be monitored every four to eight weeks following initial dosing, FDA's Antiviral Drug Products Advisory Committee recommended during its Aug. 6 meeting
Gilead has begun enrollment in two placebo-controlled trials of a 60 mg dose of adefovir dipivoxil that could provide sufficient evidence to prompt a reconsideration of the HIV therapy by FDA's Antiviral Drugs Advisory Committee.